A major goal of the DF/HCC Gl SPORE is to identify and fund projects that will lead to clinically testable hypotheses aimed at reducing the incidence and mortality rate of Gl cancers or improving the quality of life of patients with Gl cancers. The Developmental Research Program (DRP) supports short-range studies to establish the results needed to facilitate well-validated, hypothesis-driven translational projects. Although the DRP funds established investigators, an important goal is to identify and stimulate interest in Gl cancer research among groups whose current focus may be different but sufficiently related. The Developmental Projects Program is led a highly qualified committee of DF/HCC researchers who participate actively in the selection and ongoing review of pilot projects and who represent laboratory, population and clinical science across the Harvard institutions. The DRP provides the depth and flexibility required to maintain innovation in Gl SPORE activities. During the prior funding cycle, the DF/HCC SPORE supported 18 highly innovative and productive developmental projects that have enabled novel discoveries and 29 successful grant applications to further their ongoing research. The DRP will continue to support novel research in Gl cancer and has the following specific aims: 1. Solicit pilot projects in Gl cancer translational research that have significant potential for reducing the incidence and mortality rate of Gl cancer and/or improving the quality of life of patients with Gl cancers. 2. Foster collaborative efforts among SPORE investigators and with other investigators to encourage the development of new and innovative ideas and approaches. 3. Monitor the progress of the projects and provide critical feedback. 4. Encourage and assist investigators with promising preliminary data developed with support of this Program to apply for extramural peer-reviewed funding. 5. When necessary or possible, promote the most promising projects in the Developmental Research Program to full SPORE research projects.
The DF/HCC Gl SPORE Developmental Research Program seeks to support and nuture new innovative research efforts aimed at reducing the incidence and mortality rate of Gl cancers or improving the quality of life of patients with Gl cancers. To date, the Program has supported 18 novel and productive projects that are making meaningful discoveries in our understanding of Gl cancer biology, prevention, and therapy.
|Ananthakrishnan, Ashwin N; Du, Mengmeng; Berndt, Sonja I et al. (2015) Red meat intake, NAT2, and risk of colorectal cancer: a pooled analysis of 11 studies. Cancer Epidemiol Biomarkers Prev 24:198-205|
|Song, Mingyang; Gong, Jian; Giovannucci, Edward L et al. (2015) Genetic variants of adiponectin and risk of colorectal cancer. Int J Cancer 137:154-64|
|Lochhead, Paul; Chan, Andrew T; Nishihara, Reiko et al. (2015) Etiologic field effect: reappraisal of the field effect concept in cancer predisposition and progression. Mod Pathol 28:14-29|
|Inamura, Kentaro; Yamauchi, Mai; Nishihara, Reiko et al. (2015) Prognostic significance and molecular features of signet-ring cell and mucinous components in colorectal carcinoma. Ann Surg Oncol 22:1226-35|
|Serrano, César; Wang, Yuexiang; Mariño-Enríquez, Adrián et al. (2015) KRAS and KIT Gatekeeper Mutations Confer Polyclonal Primary Imatinib Resistance in GI Stromal Tumors: Relevance of Concomitant Phosphatidylinositol 3-Kinase/AKT Dysregulation. J Clin Oncol 33:e93-6|
|Rosenthal, Michael H; Kim, Kyung Won; Fuchs, Charles S et al. (2015) CT predictors of overall survival at initial diagnosis in patients with stage IV colorectal cancer. Abdom Imaging 40:1170-6|
|Arteaga, Carlos L; Engelman, Jeffrey A (2014) ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics. Cancer Cell 25:282-303|
|Wu, Chen; Kraft, Peter; Stolzenberg-Solomon, Rachael et al. (2014) Genome-wide association study of survival in patients with pancreatic adenocarcinoma. Gut 63:152-60|
|Ma, Tianle; Jang, Eun Jeong; Zukerberg, Lawrence R et al. (2014) Recurrences are common after endoscopic ampullectomy for adenoma in the familial adenomatous polyposis (FAP) syndrome. Surg Endosc 28:2349-56|
|Blaszkowsky, L S; Ryan, D P; Szymonifka, J et al. (2014) Phase I/II study of neoadjuvant bevacizumab, erlotinib and 5-fluorouracil with concurrent external beam radiation therapy in locally advanced rectal cancer. Ann Oncol 25:121-6|
Showing the most recent 10 out of 259 publications